Investigational Drug Information for Odanacatib
✉ Email this page to a colleague
What is the development status for investigational drug Odanacatib?
Odanacatib is an investigational drug.
There have been 19 clinical trials for Odanacatib.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2008.
The most common disease conditions in clinical trials are Osteoporosis, Osteoporosis, Postmenopausal, and Breast Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Summary for Odanacatib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 313 |
| WIPO Patent Applications | 196 |
| Japanese Patent Applications | 30 |
| Clinical Trial Progress | Phase 3 (2008-09-01) |
| Vendors | 52 |
Recent Clinical Trials for Odanacatib
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076) | Merck Sharp & Dohme Corp. | Phase 3 |
| A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066) | Merck Sharp & Dohme Corp. | Phase 1 |
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) | Merck Sharp & Dohme Corp. | Phase 3 |
Clinical Trial Summary for Odanacatib
Top disease conditions for Odanacatib
Top clinical trial sponsors for Odanacatib
US Patents for Odanacatib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
